ResMed (RMD): Buy, Sell, or Hold Post Q2 Earnings?
ResMed (RMD) has seen a slight loss of 2.7% over the past six months, underperforming the S&P 500. Despite this, the company exhibits solid constant currency revenue growth and an increasing free cash flow margin, indicating strong financial health. However, forecasted revenue growth for the next 12 months is a modest 2.7%, suggesting potential demand headwinds.
ResMed stock fell 1.02 percent on October 2 before earnings
ResMed Inc. stock fell 1.02% to USD 218.90 on October 2, 2026, ahead of its Q1 2027 earnings report scheduled for October 29. The company's fiscal Q4 revenue rose 8.6% to USD 1.46 billion, and adjusted earnings per share exceeded analyst estimates. Analysts maintain a "Hold" consensus with an average 12-month price target 10.4% above the October 2 closing price.
ResMed Inc. (RMD.AX) Stock Price, News, Quote & History
This article provides comprehensive financial information for ResMed Inc. (RMD.AX), including its current stock price, historical data, performance overview, and analyst insights. It details the company's operations in digital health and cloud-connected medical devices, its product offerings, and its financial highlights. The article also includes key metrics like market capitalization, P/E ratio, and earnings trends.
RSMDF | RESMED INC ORD Insider Trading
This Quiver Quantitative page provides an overview of insider trading and other financial data for RESMED INC ORD (RSMDF). It includes sections for historical prices, institutional holdings, analyst ratings, and various other metrics, though most specific data points for RSMDF are listed as "No data for this ticker" or "No recent Insider Trading." The page also promotes Quiver's premium services and data access via API.
Form 4 ResMed Inc For: 1 October By Investing.com
This article from Investing.com announces the filing of a Form 4 for ResMed Inc. on October 1st. It provides the headline for the filing and indicates that there are currently no comments on the announcement.
Stifel reiterates Hold on ResMed stock amid market share concerns
Stifel maintained a Hold rating on ResMed Inc. with a $235.00 price target, citing concerns about potential market share loss if Philips reenters the market. A survey indicated ResMed's U.S. device market share could drop from 91% to 75% under that scenario, although Philips' reentry is not expected to be imminent. Despite favorable near-term setup and positive feedback on GLP-1 drugs for CPAP, the firm is concerned about decelerating revenue growth by fiscal 2028.
STERIS (STE) Dividend Yield 2026, Date & History $STE
This article provides a detailed overview of STERIS (STE) dividend information for 2026, including its dividend yield, annual dividend, and payment history. STERIS pays quarterly dividends, has increased its dividend for 20 consecutive years, and maintains a healthy payout ratio. The report also compares STERIS's dividend performance against healthcare and NYSE averages and addresses frequently asked questions about its dividend.
RESMED INC SEC Filing (Oct 1, 2026)
This article reports on an SEC filing (ARS form) by RESMED INC (RMD) on October 1, 2026. The filing was accepted by the SEC EDGAR at 4:37 PM UTC on that date. The article also provides a summary of RMD's market data, recent news, and other SEC filings.
Inogen sharpens business focus with $25m oxygen rental unit divestment
Inogen has agreed to sell its US oxygen rental business to Rotech Healthcare for up to $25 million to refine its focus on product innovation. The deal, expected to close by Q4 2026, includes a long-term supply agreement with Rotech to expand access to Inogen's oxygen concentrators. This strategic move follows declining revenues in the rental segment and aims to strengthen Inogen's business and financial profile amidst rising COPD cases.
ResMed CFO Aaron Bloomer Acquires 9,072 Shares via Performance RSU Grant
ResMed CFO Aaron Bloomer acquired 9,072 shares of ResMed common stock on August 14, 2026, at no cost, stemming from a performance-based restricted stock unit grant. The shares were earned after the compensation committee certified that performance metrics were met, with the RSUs vesting one-third annually from the June 1, 2026 grant date. Following this transaction, Bloomer directly owns 9,072 shares of ResMed common stock.
ResMed Global General Counsel Michael Rider Acquires 3,230 Shares via Performance RSU Grant
ResMed's Global General Counsel and Secretary, Michael J. Rider, acquired 3,230 shares of ResMed common stock on August 14, 2026. This acquisition was a result of performance-based restricted stock units (RSUs) granted on November 20, 2025, which vested after applicable performance metrics were met. Following this transaction, Rider's direct beneficial ownership of ResMed common stock totals 12,718 shares.
Form 4 ResMed Inc For: 1 October By Investing.com
This article reports on a Form 4 filing for ResMed Inc. (RMD) on October 1, 2026. Form 4s disclose transactions by company insiders, but the article does not provide specific details of the transaction. It is primarily a placeholder announcement for the regulatory filing.
Form 4 ResMed Inc For: 1 October
This article from Investing.com is a brief report indicating a Form 4 filing for ResMed Inc. on October 1. Form 4 filings typically disclose changes in beneficial ownership of securities by company insiders. The article provides no further details beyond the company name, form type, and date.
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
Resmed (NYSE: RMD) is scheduled to report its first-quarter fiscal 2027 earnings on Thursday, October 29, 2026, after the market closes. The company will also host a live webcast and conference call to discuss its results, followed by a question-and-answer session for analysts and investors. Interested parties can access the webcast or dial into the conference call for participation.
A 10% dividend increase is part of ResMed (RMD)'s FY2027 stockholder return plan.
ResMed (RMD) announced plans for over $1.85 billion in stockholder returns for fiscal year 2027, including approximately $1.5 billion in share repurchases and a 10% increase in the quarterly dividend to $0.66 per share. This strategy follows a strong fiscal year 2026 with 8% constant currency revenue growth and 17% non-GAAP diluted earnings per share growth. The company also detailed corporate governance changes, including the election of 10 directors and the ratification of PricewaterhouseCoopers LLP as its fiscal 2027 auditor.
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
ResMed (NYSE: RMD, ASX: RMD) announced it will release its financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results, which will be accessible via their investor relations website. A replay of the webcast will also be available on their website and via a phone replay for a limited period.
Meiragtx Holdings Plc (MGTX-Q) Stock Price and News
This article provides comprehensive information on Meiragtx Holdings Plc (MGTX-Q), including its stock price, recent news, financial data, and analyst ratings. It highlights various news items such as board appointments, strategic investments, and financial results, along with stock performance metrics. The company profile identifies MeiraGTx as a clinical-stage gene therapy company developing treatments for inherited and acquired disorders.
Operating margin % of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA
This article displays the operating margin percentage for ResMed Inc. CHESS Depositary Interests (HAN:RMEA) on the TradingView platform. It provides financial data for the company's stock listed on the Hannover Stock Exchange. The content is primarily a data presentation page, indicating market status as closed with no trades.
Price to cash flow ratio of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA
This article provides the "Price to cash flow ratio" for ResMed Inc. CHESS Depositary Interests (RMEA) on the Hannover Stock Exchange. It indicates that the market is currently closed with no trades recorded. The page is primarily a financial data point for ResMed Inc.
ResMed stock trades at EUR 195.18 after RBC raises target
RBC raised its price target for ResMed stock from USD 244.00 to USD 262.00 on September 15, 2026, upgrading its rating to Outperform. The company reported fiscal 2026 revenue of USD 5.7 billion, an 8.00 percent year-over-year increase, and adjusted EPS of USD 2.95 for the last reported quarter. Despite a current trading price of EUR 195.18 at Lang & Schwarz, reflecting a slight dip, the new target suggests a significant directional upside, though analyst consensus on valuation remains varied.
Can ResMed (ASX:RMD) Hit Its Outlook After Retiring the Astral Ventilator?
ResMed (ASX:RMD) has reaffirmed its full-year outlook despite facing a revenue headwind from a field safety action related to its Astral ventilator, which the company plans to retire. The medical device manufacturer expects to absorb the impact due to the Astral platform being a relatively small part of its overall revenue compared to its core sleep apnoea business. Analysts are closely watching gross margin progress and operating expense discipline, alongside broader market sentiment, to assess the stock's future performance.
Net income of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA
This article provides a brief financial update on ResMed Inc. CHESS Depositary Interests (RMEA) on the Hannover Stock Exchange, specifically noting its net income. The content appears to be a financial data snippet from TradingView, indicating a period value, change, and percentage change, but the specific figures are not displayed in the provided text.
Net debt of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA
This article provides financial information specifically on the net debt of ResMed Inc. CHESS Depositary Interests (RMEA) traded on the Hannover Stock Exchange. It indicates that the market is currently closed with no trades. The article also mentions that financial data is provided by ICE Data Services and reference data by FactSet.
Is ResMed A Better Way Than Stryker To Own Medical Device Growth?
This article compares ResMed (RMD) and Stryker (SYK) as medical device investment options, noting their similar growth rates over the past three years. While Stryker is a larger company with a higher price-to-earnings ratio, ResMed shows better profitability, lower debt, and faster revenue growth, making it appear more favorable despite Stryker's lower price-to-sales ratio and elevated order backlog. The author concludes that the evidence favors ResMed, unless Stryker's full-year 2026 growth exceeds its own forecasted range.
ResMed stock last trades at USD 219.41 on September 28, 2026
ResMed stock last traded at USD 219.41 on September 28, 2026, marking a 1.17 percent decrease. The company reaffirmed its fiscal 2027 guidance for core constant-currency revenue growth of 5% to 7% and core EPS growth of 12% to 14%. This guidance includes an expected $75 million revenue headwind from an Astral field safety action, as ResMed plans to discontinue the Astral platform.
Is Inspire Medical Systems (INSP) Expensive As Inspire V Becomes The Main Growth Story?
Inspire Medical Systems (INSP) is undergoing a significant product transition to its Inspire V system, backed by clinical evidence and efforts to improve patient access. Despite recent stock price gains, the company's shares are still down significantly year-to-date and over three years. While analysts suggest a fair value of $60.40, indicating the stock is currently overvalued, its P/E ratio of 14.7x is well below peers, presenting a conflicted outlook for investors.
ResMed Inc. (NYSE:RMD) Receives Consensus Recommendation of "Hold" from Brokerages
ResMed Inc. (NYSE:RMD) has received a consensus "Hold" recommendation from sixteen brokerages, with nine analysts rating it a "hold" and seven a "buy." The average 12-month price target is $241.69. The company recently exceeded quarterly earnings expectations, reporting $2.95 EPS on $1.46 billion in revenue, and increased its quarterly dividend to $0.66.
ResMed (RMD) Stock Forecast and Price Target 2026 $RMD
ResMed (RMD) has a consensus "Hold" rating from 16 Wall Street analysts, with an average price target of $241.69, suggesting an 8.68% upside from its current price of $222.38. Recent analyst actions include both upgrades and downgrades, with positive sentiment due to strong financial performance and dividend increases, but negative sentiment from insider selling, stock volatility, and increased short interest. The company faces competitive pressures and margin challenges despite its strong position in the sleep apnea treatment sector.
ResMed stock trades at USD 221.89 after RBC target hike
ResMed stock is trading at USD 221.89 after RBC Capital upgraded its rating to Outperform and raised its price target from USD 244 to USD 262. The company recently reported strong quarterly revenues of USD 1.46 billion and increased its quarterly dividend to USD 0.66 per share. Despite the positive analyst upgrade and earnings report, the stock remains below its 52-week high, and the broader analyst consensus is a "Hold."
ResMed stock heads into the open after September 24 data
ResMed stock closed its last Nasdaq session on September 24, 2026, with the Nasdaq Composite up 0.01 percent. The company was also a topic of discussion on Bloomberg regarding its expansion in sleep health and investment in Noctrix Health. Today's trading on September 25, 2026, follows a mixed US market close, with oil prices advancing and Treasury yields reaching a two-decade high.
ResMed CEO Farrell: Every Hour of CPAP Use Cuts Healthcare Costs 7%
ResMed CEO Mick Farrell highlights that every hour of CPAP machine use, up to seven hours, reduces a patient's total healthcare costs by 7%, effectively halving costs for fully adherent patients. This insight is driven by ResMed's 12-year investment in cloud-connected devices, yielding an 87% adherence rate and enabling AI products like Project Dawn and SmartComfort. Farrell views sleep as a "horizontal" health input impacting numerous diseases and is expanding ResMed's focus beyond sleep apnea into conditions like insomnia and restless leg syndrome through strategic acquisitions and R&D.
STERIS plc (Ireland) (STE) Stock forecasts
Argus has lowered its target price for STERIS plc (Ireland) (STE) to $230.00. STERIS is a medical technology company specializing in sterilization services and infection prevention. The report was published on September 23, 2026.
ResMed Inc. (RMD) Stock Price, News, Quote & History
This article provides a comprehensive overview of ResMed Inc. (RMD), including its current stock price, financial summary, key performance indicators, and company profile. It details ResMed's business in digital health and cloud-connected medical devices, operating in Sleep and Breathing Health and Residential Care Software segments. The report also includes analyst insights, earnings trends, and valuation measures for investors.
ResMed stock reports 10 percent fiscal revenue growth
ResMed (RMD) reported a 10% increase in fiscal 2026 revenue, reaching USD 5,653 million, and raised its quarterly dividend by 10% to USD 0.66 per share. The company's stock was trading at USD 222.30, below its 52-week high, while RBC upgraded its rating to Outperform with a price objective of USD 262.00. Strong operating cash flow and a healthy operating margin contribute to the company's solid financial performance.
IDEXX Laboratories, Inc. (IDXX) stock price, news, quote and history
This article provides a comprehensive overview of IDEXX Laboratories, Inc. (IDXX) stock, including its current price, historical data, financial performance, and analyst insights. It details the company's operations across companion animal, water quality, and livestock segments, highlighting its diverse product and service offerings in diagnostics and research. The report also includes key financial metrics, performance comparisons against the S&P 500, and analysts' price targets.
Intuitive Surgical, Inc. (ISRG) Options Chain - Yahoo Finance
This article provides the options chain for Intuitive Surgical, Inc. (ISRG) on Yahoo Finance. It indicates that there are currently no calls or puts available, with options data delayed by 15 minutes. The page also displays current stock information for ISRG, showing a price of 396.65 with a -1.35% change as of 1:49:36 p.m. EDT.
ResMed Inc. $RMD Shares Sold by Baird Financial Group Inc.
Baird Financial Group Inc. significantly reduced its stake in ResMed Inc. (NYSE:RMD) by 98.6% in the second quarter, selling 104,473 shares. Despite this, other institutional investors, such as Allworth Financial LP and Giverny Capital Inc., increased their positions in the medical equipment provider. ResMed reported strong financial results for the quarter, beating analyst estimates, increased its quarterly dividend, and received mixed ratings from analysts with a consensus "Hold" rating.
ResMed stock slips 0.73 percent ahead of the open
ResMed (NYSE: RMD) stock declined by 0.73 percent, closing at USD 221.97 on September 22, 2026, underperforming the S&P 500. The company's shares traded between USD 221.88 and USD 227.90 with a volume of 979,415 shares, below its average. ResMed's next estimated earnings date is October 29, 2026, and its stock is down 7.85 percent year to date.
Is Generac Holdings Inc. (GNRC) Stock a Top AI Infrastructure Play After $2.4 Billion Amazon Deal?
Generac Holdings Inc. (GNRC) is transitioning to become a major power infrastructure supplier for the data center industry, bolstered by a new long-term supply agreement with Amazon worth an estimated $2.4 billion for backup generators in 2027 and 2028. This deal expands Generac's exposure to hyperscale customers and AI-related infrastructure spending, contributing to an already substantial data center backlog. While the agreement offers significant growth potential and revenue visibility, Generac faces risks related to production capacity expansion, delivery schedules, and customer concentration with Amazon.
Weekly Recap: FY26 revenue & EPS growth and RBC upgrade, $1.5B buyback
ResMed Inc. (NYSE:RMD) reported strong FY26 financials with $5.7B in revenue and a 16% increase in EPS, alongside robust sleep-device sales and a positive outlook for FY27. RBC upgraded RMD to Outperform, raising its price target to $262, citing increased demand for sleep-apnea devices and a $1.5B buyback. The company also returned approximately $1 billion to shareholders.
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
ResMed (NYSE: RMD) is targeting 12%-14% core EPS growth and 5%-7% core constant-currency revenue growth, driven by increased therapy adoption, resupply activities, product innovation, and margin improvements. The company noted that patients using both GLP-1 drugs and positive airway pressure therapy show higher therapy-start and resupply rates, potentially adding 50-125 basis points to Americas sleep-device growth. ResMed is also strategically reshaping its portfolio through acquisitions like Noctrix, divestments such as MatrixCare, and discontinuing its Astral platform to focus on newer devices.
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
ResMed (NYSE:RMD) projects a 12%-14% core EPS growth and 5%-7% constant-currency revenue growth, driven by increased therapy adoption, product innovation, and margin improvements. The company notes that patients using both GLP-1 drugs and positive airway pressure therapy show higher treatment initiation and resupply rates, potentially boosting Americas sleep-device growth by 50-125 basis points. ResMed is also strategically reshaping its portfolio through acquisitions like Noctrix and divestitures such as MatrixCare, while discontinuing the Astral platform.
ResMed Stock And Senior Healthcare Shares Linked To Medicare Spending Trends
This article examines how trends in Medicare spending and the aging U.S. population influence senior consumer and healthcare stocks. It highlights three companies—American Healthcare REIT (AHR), ResMed (RMD), and CareTrust REIT (CTRE)—that are positioned to be affected by these demographic and spending shifts. The piece emphasizes the importance of analyzing each company's financial narrative to understand how pricing power, leverage, and capital costs might impact their margins and dividend capacity.
ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures
ResMed Inc. (RMD) is well-positioned for growth in the global obstructive sleep apnea (OSA) treatment market due to its robust product portfolio, including CPAP and APAP machines and accessories. Despite strong Q4 fiscal 2026 revenue growth, the company faces risks from increased competition, particularly Philips Respironics' potential return to the US market, and recently issued a weaker-than-expected 2027 revenue forecast. Investors are weighing ResMed's market leadership against these competitive and operational pressures, as well as the temporary suspension of Astral ventilator sales.
Nykredit A S Makes New Investment in ResMed Inc. $RMD
Nykredit A/S has made a significant new investment in ResMed Inc. (NYSE:RMD), purchasing 338,702 shares valued at approximately $66 million in the second quarter. This move aligns with other institutional investors increasing their stakes, bringing total institutional ownership to nearly 55%. Despite a "Hold" consensus rating from analysts, ResMed has shown strong financial performance, exceeding earnings expectations, and recently increased its quarterly dividend.
Resmed Inc. : RBC Raises to Outperform From S
RBC Capital Markets has upgraded its rating for Resmed Inc. (RMD) from Sector Perform to Outperform. This rating change reflects a more positive outlook on the company's stock performance by RBC analysts.
Bank of America Corp DE Buys New Stake in ResMed Inc. $RMD
Bank of America Corp DE has acquired a new stake in ResMed Inc. (NYSE:RMD) during the second quarter, purchasing 775,424 shares valued at approximately $151.1 million, which represents a 0.53% ownership in the medical equipment provider. Other institutional investors also increased their holdings, with institutional investors and hedge funds collectively owning 54.98% of the company's stock. ResMed recently reported strong quarterly earnings, beating analyst estimates, and increased its quarterly dividend.
GE HealthCare Technologies (GEHC) Stock Forecast and Price Target 2026
GE HealthCare Technologies (GEHC) currently holds a "Hold" consensus rating from 21 Wall Street analysts, with an average 12-month price target of $77.73, representing a potential upside of 19.93% from its current price of $64.81. Analysts issued 11 hold ratings and 10 buy ratings. The article also details bull and bear cases, including the company's strategic push into AI-enabled solutions and potential acquisition talks, versus legal investigations, increased short interest, and competitive pressures.
Atkore stock hits 52-week high at 94.63 USD By Investing.com
Atkore International Group Inc. (ATKR) recently reached a 52-week high of $94.62, representing a 76% surge from its 52-week low. This surge is attributed to strong performance and investor confidence, with the stock showing a 61% 1-year return and a 51% year-to-date return. The company is also in the process of being acquired by Prysmian S.p.A. for $95.00 per share, a development that led Roth/MKM to downgrade Atkore from Buy to Neutral, while increasing the price target to $92.
ResMed Shares Jump Following RBC Capital Upgrade to Outperform
ResMed (RMD) stock surged 3% after RBC Capital Markets upgraded it to Outperform and raised its price target, citing strong growth in sleep apnea device sales, especially internationally. The upgrade was further bolstered by a Class 1 recall of a competing product from React Health, which RBC believes will drive more demand towards ResMed. Analysts anticipate high single-digit EPS growth for ResMed over the next three years, even with projected competition from Philips Respironics.
